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Recent studies have shown diagnostic and prognostic values of circulating tumor cells (CTCs) and disseminated
tumor cells (DTCs) in various cancers, including ovarian cancer. We aimed to evaluate the association of CTCs and/
or DTCs with the clinical outcomes of ovarian cancer. Clinical studies of CTCs/DTCs of ovarian cancer were included
for systematic review and meta-analysis. A total of 236 studies were screened but only 16 qualified studies with
1623 subjects were included. Odds ratio (OR) showed CTCs/DTCs were not significantly associated with serous
carcinoma (OR = 0.71 [0.49, 1.05]), lymph node metastasis (OR 1.14 [0.67, 1.93]), and residual disease (OR 1.45
[0.90, 2.34]); but significantly associated with advanced tumor staging (OR = 1.90 [1.02, 3.56]). The overall pooled
hazard ratio (HR) of CTCs/DTCs on OS and PFS/DFS was 1.94 [1.56– 2.40] and 1.99 [1.59–2.50], respectively. Subgroup
analyses revealed that CTCs were significantly associated OS (HR 1.97 [1.50-2.58]) and PFS/DFS (HR 2.52 [1.83-3.48]),
while DTCs was significantly associated OS (HR 1.89 [1.33, 2.68]) and PFS/DFS (HR 1.60 [1.17, 2.19]). Meta-analysis
showed strong relationship of CTCs/DTCs with advanced staging, treatment response and poor prognosis in
patients with ovarian cancer.
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Ovarian cancer is the most frequent cause of death
amongst gynecological cancers worldwide. Majority of
cases diagnosed in late stage of the disease and resulted
in poor survival [1]. The five-year survival rate of
patients with ovarian cancer is only around 30 % in
Stage III or IV [2]. The reasons of delayed diagnosis are
partly due to lack of sensitive signs and symptoms and
effective screening methods [3]. Although survival has
been improved with the use of cyto-reduction surgery
along with platinum- and/or taxane-based chemotherapy,
nearly 80 % eventually relapse within 5 years [4]. There-
fore, methods that help detection of ovarian cancer in
early stage and monitoring of tumor progression have
great potential to improve survival of the patients.* Correspondence: longcui@link.cuhk.edu.hk
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creativecommons.org/publicdomain/zero/1.0/It was considered that ovarian cancer spreads primarily
through direct dissemination in the abdominal cavity.
While the presence of disseminated tumor cells (DTCs) in
bone marrow of patients with ovarian cancer have been
reported [5, 6]. However, bone marrow sampling is rather
an invasive procedure, which is not widely accepted in the
clincial management. In recent years, focus has been
shifted to the detection of circulating tumor cells (CTCs)
in peripheral blood. CTCs are tumor cells release from the
primary tumor and then circulate through the blood-
stream, resulting in spreading to different organs and sub-
sequent outgrowth of the tumor cells in new
microenvironment. These CTCs thereby have the poten-
tial to contribute to the development of local and system-
atic relapses [7]. Either DTCs or CTCs have potential to
predict prognosis and to monitor treatment efficacy in
cancer patients. Presence of CTCs has been reported in
several solid tumors, including breast [8], colorectal [9],
lung [10], kidney [11], esophageal [12], liver [13], prostatee distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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DTCs in ovarian cancer patients had been investigated,
most of them demonstrated that CTC or DTC is associ-
ated with poor clinical outcome [17–22]. However, other
studies failed to show the positive correlation [5, 23, 24]
and even demonstrated negative association in terms of
progression free survival/disease free survival (PFS/DFS)
and overall survival (OS) [25, 26]. The prognosis value of
CTCs/DTCs in ovarian cancer remains controversial. A
recent systematic review of CTCs and DTCs in ovarian
cancer concluded the association of CTCs and DTCs with
adverse clincopathological characteristics and poor clinical
outcomes [27], but no appropriate statistics and detailed
analysis were provided.
The objective of this study was to conduct a meta-
analysis of published clinical studies of CTCs/DTCs in
ovarian cancer and to investigate the association of CTCs/
DTCs with clinical outcomes.
Methods
An independent systematic review of the literature across
PubMed and EMBASE database was conducted on April
27, 2015. The search strategy included keywords such as
“ovarian cancer”, “ovarian carcinoma”, “circulating tumor
cell (s)”, “disseminated tumor cell (s)”, and “prognos*”.
Only studies published in peer reviewed journals were
included, data from letters and conference abstracts were
not included. The study selection process is shown in
Fig. 1 and search strategies and results are provided in
Additional file 1.
We recorded the following information from each
eligible study, including author’s name, publication year,Fig. 1 Flow diagram of study inclusion decisionsnumber of participants, sampling time, methods and
results of CTCs/DTCs detection, and OS and/or PFS/
DFS. We also collected clinopathological parameters,
including histology, lymph node metastasis, cancer stage,
residual diseases and treatment response. Histological
types of the ovarian cancer were classified mainly as
serous carcinoma or non-serous carcinoma. Lymph node
metastasis was confirmed by pathological examination in
the lymph nodes collected during cyto-reduction sur-
gery. According to FIGO staging of ovarian cancer, Stage
I and Stage II were combined and Stage III and Stage IV
were combined. Complete resection was referred to no
residual disease for no residual tumor, minimal residual
disease for residual tumor in 1 cm or less, and gross
residual disease for residual tumor in greater than 1 cm
[28, 29]. Treatment response was classified as platinum-
sensitive as defined when the patients with platinum-
free interval of ≥ 6 months or platinum-resistant disease
as defined when the patients relapse ≥ 6 months from
the end of first line platinum-base therapy [30].
Inclusion criteria included: 1) clinical studies measured
CTCs/DTCs, regardless of randomized or case-controlled
studies; prospective or retrospective studies; and detection
methods; 2) study outcomes provided clinical and patho-
logical information; and 3) studies provided information
of survival outcomes such as OS and PFS/DFS. Studies
were excluded based on: 1) laboratory studies without
clinical outcomes; 2) review, editorials, and commentary
articles; 3) no survival data or insufficient data to be
extracted. Two reviewers independently screened titles
and abstracts of the studies for inclusion and then
retrieved the full text for details data extraction.
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PRISMA and MOOSE Checklist and the quality of the
included studies was assessed with the Newcastle-Ottawa
Scale (NOS) for cohort studies [31]. (Additional file 2 and
Additional file 3). We examined the association between
CTCs/DTCs and clinopathological outcomes. Odds ratio
(OR) was used as the measure of index to describe the
association. Survival analysis for natural logarithm of HR
(lnHR) and standard error (SE) were calculated. If these
statistical variables were not explicitly provided in studies,
lnHR, SE and p values will be calculated from the available
numerical data and Kaplan-Meier survival curves accord-
ing to Tierney et al. [32]. Fixed or random-effects models
will be employed to calculate the pooled hazards ratio
(HR) with 95 % confidence intervals (CIs) for survival.
Heterogeneity among studies was conducted by Cochran-
Mantel-Haenszel test with the Cochran’s Q test and
P values. When P value less than 0.05, a random-effects
model was used. Otherwise, a fixed-effects model was pre-
sented. Subgroup analyses of sample types and detection
method were performed. Publication bias was assessed
using funnel plot, then further examined by Begg and
Egger’s test [33]. All statistical analyses were conducted
using the software R/metafor version 2.14.0. P values less
than 0.05 were considered statistically significant.Results
236 records were identified from the literature search.
The selection processes are summarized in Fig. 1. After
screening of titles and abstracts, 220 studies were
excluded. 91 were irrelevant, 13 were review articles, 4
were letter/editorial/survey articles, 89 were conference
abstracts/reports, and 23 were duplicated publications.
Finally, 16 studies met the inclusion criteria for data
extraction. We recorded the following information of
each eligible study: author’s names, year of publication,
number of patients analyzed, sampling timing, CTCs
and/or DTCs studied, detection method of CTCs/DTCs,
markers used for the detections, definition of positive
CTCs/DTCs and survival data, and results of the studies.
Details of the included studies are summarized in Table 1.
In total, there were 1623 patients, and the sample
size of each study was ranged from 43 to 216. Most
studies were published between 2002 and 2014,
4 studies from US, 11 studies from Europe and 1 study
from Asia. There were 6 studies including 459 patients
recorded the prognostic values of DTCs detected in
bone marrow and 10 studies including 1164 patients re-
corded the prognostic values of CTCs detected in per-
ipheral blood. Seven out of 16 studies had positive
results of CTC/DTC effects on survival. Four out of 16
had negative results, remaining 5 studies had con-
troversial conclusions.Associations of CTCs/DTCs with clinicopathological
parameters were analyzed (Table 2). Six studies [5, 17,
25, 34–36] with defined pathological diagnosis of serous
carcinoma or non-serous carcinoma were included to
study the relationship between CTCs/DTCs and histo-
logical types of the ovarian cancer. The estimated pooled
OR was 0.72 (95 % CI: 0.48–1.06; Z = −1.71; P = 0.088
fixed-effect), demonstrating that CTCs were not associated
with the tumour histology. The heterogeneity among stud-
ies was not significant (Q = 5.24, p = 0.387). Three studies
[17, 35, 37] assessing metastasis in lymph node or not were
included to study the relationship between CTCs/DTCs
and lymph node metastasis. Of the results showed that
CTCs/DTCs were not significantly associated with lymph
node metastasis in ovarian cancer patients (pooled OR =
1.14; 95 % CI: 0.67–1.93; Z = 0.481; P = 0.630 fixed-effect).
The heterogeneity among studies was not significant (Q =
3.82, p = 0.148). In six studies [5, 17, 25, 35–37], there was
significant association between CTC and advanced tumor
stage (Stage III-IV, pooled OR = 1.90; 95 % CI: 1.02–3.56;
Z = 2.02; P = 0.044 fixed-effect), indicating that CTCs/
DTCs were significantly increased with the risk of disease
progression in ovarian cancer. The heterogeneity among
studies was not significant (Q = 10.84, p = 0.055). Three
studies [17, 25, 35], were included to study the relationship
between CTCs/DTCs and debulking surgery, CTCs were
not significantly associated with the optimal or suboptimal
surgery in ovarian cancer patients (pooled OR =
1.45; 95 % CI: 0.90–2.34; Z = 1.53; P = 0.126 fixed-effect).
However, one study [35] showed that DTCs significant as-
sociation with residual diseases (OR = 2.31, CI: 1.19-4.50).
The heterogeneity among studies was not significant (Q =
3.71, p = 0.157). Two studies [34, 35] assessing platinum
sensitive or resistant were included to study the relation-
ship between CTCs and treatment response, the result
showed that CTCs were significantly associated with treat-
ment response in ovarian cancer patients (pooled
OR = 0.55; 95 % CI: 0.34–0.90; Z = −2.37; P = 0.017 fixed-
effect). The heterogeneity among studies was not signifi-
cant (Q = 0.930, p = 1.0000).
OS was analyzed in 7 studies [17–19, 22, 34, 35, 37]
including 965 patients in total. Since the heterogeneity
across the studies was larger than 0.05 (Q = 3.3, P = 0.770),
the estimated pooled HR for studies was calculated using
a fixed effect model. The pooled HR showed that CTCs/
DTCs were significantly associated with OS (HR = 1.94;
95 % CI: 1.56– 2.40; Z = 6.02; P < 0.0001 fixed effects),
indicating CTCs/DTCs significantly increased the risk of
overall mortality in ovarian cancer (Fig. 2).
PFS/DFS were analyzed in 6 studies [18, 19, 22, 34, 35, 37]
including 885 patients in total. Because the heterogeneity
across the studies was also larger than 0.05 (Q = 9.11, P =
0.105), the estimated pooled HR for studies was calculated
using a fixed effect model. The estimated pooled HR
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with PFS/DFS (HR = 1.99; 95 % CI: 1.59–2.50; Z = 6.01;
P < 0.0001 fixed effects), indicating CTCs/DTCs significantly
increased with the risk of low survival in ovarian cancers
(Fig. 3).
Results for subgroup analysis is summarized in Table 3.
CTCs and DTCs could be detected in peripheral blood
(PB) and bone marrow (BM), respectively, we divided
the studies into either CTCs or DTCs subgroups toinvestigate the influence of sampling types on the sur-
vival of patients with ovarian cancer. CTCs from PB
were detected and correlated with PFS/DFS and OS in 4
studies [18, 19, 34, 35] and 5 studies [17–19, 34, 35], re-
spectively. The results showed that CTCs were signifi-
cantly associated with both PFS/DFS (HR =2.52 [1.83,
3.48], z = 5.614 %, p < 0.0001) and OS (HR = 1.97 [1.50,
2.58], z = 4.878, p < 0.0001). DTCs from BM were de-
tected and correlated with PFS/DFS and OS in 3 studies
Table 2 Association of CTCs/DTCs and clinicopathological datasets
No. of Studies
(sample size)
OR (95 % CI) Model OR, p value P-H Begg’s test,
p value
Serous carcinoma vs. Non-serous carcinoma 6 (789) 0.71 [0.49,1.05] FE 0.0878 0.3876 0.719
FIGO stage III-IV vs. FIGO stage I-II 6 (687) 1.90 [1.02, 3.56] FE 0.0438 0.0546 0.1361
Lymph node metastasis vs. No lymph node metastasis 3 (404) 1.14 [0.67, 1.93] FE 0.6304 0.1484 1.0000
Suboptimal debulking vs. optimal debulking 2 (141) 0.78 [0.32, 1.88] FE 0.5751 0.3232 1.0000
Platinum sensitive vs. Platinum resistant 2 (508) 0.55 [0.34, 0.90] FE 0.0178 0.9298 1.0000
FE Fixed-Effects; P-H P value –Heterogeneity
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significantly associated with PFS/DFS (n = 2, HR = 1.60
[1.17, 2.19], z = 2.926, p < 0.0034) and OS (n = 2, HR =
1.89 [1.33, 2.68], z = 2.358, p < 0.0004). These suggested
both CTCs and DTCs could be useful for evaluating
prognostic value of ovarian cancer.
Four studies detected CTC by RT-PCR methods [17, 19,
26, 35]. Eleven studies detected by CellSearch system or
other IHC methods [5, 6, 20–25, 34, 37, 38]. We divided
the studies into molecular-based and immunological-
based detection methods for sub-group analysis. For
molecular-based subgroup, HR and 95 % CI for OS was
1.78 [1.24, 2.54] (z = 3.1369, p < 0.0001) among three stud-
ies [35, 19, 17] whereas HR and 95 % CI for PFS/DFS was
3.49 [1.95, 6.24] (z = 4.2007, p < 0.0001) among two stud-
ies [35, 19]. For immunological-based subgroup, HR and
95 % CI for OS and PFS/DFS was 1.96 [1.48, 2.60] (z =
3.5380, p < 0.0001) and 1.70 [1.33, 2.19] (z = 4.1628,
p < 0.0001) amongst three studies [37, 34, 22], respectively.
The results indicated that both RT-PCR and IHC detec-
tion methods were able to detect CTCs/DTCs in predict-
ing patient’s survival.
Begg’s funnel plot was used to identify individual studies
in relation to their respective standard deviation, which re-
vealed no evidence of asymmetry (p = 0.2389) in an overallFig. 2 Forest plot of HRs for OS from 7 studies (965 patients)analysis of the studies of OS (Fig. 4a). There was no
evidence of asymmetry (p = 0.0167) in an overall analysis
of the studies of PFS/DFS (Fig. 4b). Using Egger’s test,
there was no significant publication bias for overall ana-
lysis of the studies of OS (p = 0.3405), but significant bias
was found for overall analysis of the studies of PFS/DFS
(p = 0.0051). There was no publication bias for all subse-
quent subgroup analyses.Discussion
In our systematic review and meta-analysis, the results
showed strong association of CTCs/DTCs not only with
advanced staging and poor prognosis in patients with
ovarian cancer, but also with treatment response. Al-
though there was publication bias in Pearl et al. 2014
and Kuhlmann et al. 2014 studies for PFS/DFS group
analysis, CTCs/DTCs were still significantly associated
with PFS/DFS after bias removed. The combined HRs of
CTCs/DTCs for OS and PFS/DFS was nearly 2.0,
suggesting that the detected CTCs/DTCs had a strong
predictive values for OS and PFS/DFS. For CTCs alone,
the pooled HRs of CTCs for PFS/DFS were more than
2.0, indicating that CTCs could be used as a prognostic
marker for ovarian cancer.
Fig. 3 Forest plot of HRs for PFS/DFS from 6 studies (885 patients)
Cui et al. Journal of Ovarian Research  (2015) 8:38 Page 6 of 10Association of CTCs/DTCs with clinopathological
characteristics revealed that CTCs/DTCs significantly
associated with advanced tumor stage and treatment
response. No significant association were observed with
histological subtypes, debulking surgery and lymph
nodes metastasis. Experimental studies had demon-
strated detection of CTCs were significantly correlated
with the advanced stage [39, 40]. It may be one of the
reasons why these patients have a high incidence of
tumor recurrence after surgical resection. Residual
disease after cyto-reduction surgery was associated with
poor prognosis of ovarian cancer [41]. Moreover, in
terms of the response to chemotherapy, CTCs/DTCs
were significantly associated with treatment response. It
suggested that CTCs/DTCs could be used as an early
predictive marker of tumor response in ovarian cancer
patients undergo chemotherapy. In our meta-analysis,
detection of CTC was not significantly associated with
the evidence of optimal or suboptimal surgery, only one
study [35] reached a conclusion of positive (OR 2.31
[1.19-4.50]) with residual diseases by detecting DTC.
This confusing result could be only resolved when more
studies were conducted to confirm clinical values of the
CTCs in ovarian cancer. On the other hand, ovarian
cancer grows and recurs mainly in direct dissemination
in the abdominal cavity [42]. Lymph nodes metastasis
occur only when cancer cells invade lymphatic vessels
while CTCs/DTCs occur only when cancer cells invade
blood vessels. Although both lymph nodes metastasis
and CTCs/DTCs were associated with poor prognosis in
ovarian cancer patients [43], CTCs/DTCs were not
significantly associated with lymph nodes metastasis,
indicating the cancer cells may spread differently.
In subgroup analysis, comparing the HR of CTCs with
the HR of DTCs for survival, CTCs for PFS/DFS was lar-
ger than DTCs for PFS/DFS (HR 2.50 vs 1.60) whileCTCs for OS was similar to DTCs for OS (HR 1.97 vs
1.89). This indicated that CTCs could be more sensitive
than DTC in evaluating tumor progression. In addition,
detection of CTC seems more practical than DTC in
terms of monitoring of progression of disease. Although
bone marrow is the major site of metastasis [44], CTC
could be systematically evaluated in peripheral blood
stream. For CTCs/DTCs detection methods, IHC and
RT-PCR were two main methods. Compared with IHC,
although both methods were significantly associated
with poor prognosis, RT-PCR seems to be more sensitive
than IHC (HR 3.49 vs 1.70) [45]. This suggested that
RT-PCR could be a promising methods in identifying
CTC/DTC in patients with ovarian cancer. However, sig-
nificant challenges include the frequency of both false
positive and false negative results and the difficulty in
quantitating relative levels of expression. Although gen-
omic analyses of cell-free DNA fragments in peripheral
blood have been reported [46, 47] and recently extended
to the whole-genome scale [48], in situ and morpho-
logical analyses by fluorescent in situ hybridization
(FISH) and IHC will be not possible. Apart from nucleic
acid-based detection of CTC, detection and isolation of
CTC by virtue of their physical properties distinguished
from normal blood cells, including cell size, cell density,
membrane charge and migratory properties, has advan-
tageous to analyze CTCs with intact functional cancer
cells circulating in peripheral blood [49]. It shows
promising in CTC detection but requires further valid-
ation [50, 51].
CTCs/DTCs were associated with a poor survival out-
come in our meta-analysis. However, there were limita-
tions in this meta-analysis. Firstly, the number of
patients in each study were relatively small. The results
should be confirmed by larger prospectively clinical
study. Secondly, the methodology varied in different
Table 3 Subgroup analyses of CTCs/DTCs
Subgroup analysis PFS/DFS OS
No. of Studies
(sample size)




HR (95 % CI) Model P value P-H Begg’s test,
p value
Total (CTCs and DTCs) 6 (885) 1.99 [1.59, 2.50] FE <.0001 0.1047 0.0167 7 (965) 1.94 [1.56 2.40] FE <.0001 0.7704 0.2389
Sampling from BM (DTCs) 2 (181) 1.60 [1.17, 2.19] FE 0.0034 0.4417 1.000 2 (181) 1.89 [1.33, 2.68] FE 0.0004 0.9687 1.0000
Sampling from PB (CTCs) 4 (704) 2.52 [1.83, 3.48] FE <.0001 0.2064 0.3333 5 (784) 1.97 [1.50, 2.58] FE <.0001 0.5147 0.0833
Total (IHC and RT-PCR) 5 (756) 1.91 [1.51, 2.40] FE <.0001 0.2037 0.0833 6 (818) 1.89 [1.52, 2.36] FE <.0001 0.7839 0.7194
Detected DTCs by IHC 3 (397) 1.70 [1.33, 2.19] FE <.0001 0.5934 1.0000 3 (397) 1.96 [1.48, 2.60] FE 0.0004 0.9314 1.0000
Detected CTCs by RT-PCR 2 (359) 3.45 [1.95, 6.24] FE <.0001 0.9452 1.0000 3 (439) 1.78 [1.24, 2.54] FE 0.0017 0.3463 0.3333












Fig. 4 Begg’s funnel plots of publication bias summary. a Overall survival (OS); b Progression-free Disease-free survival (PFS/DFS)
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tection methods and defining the presence of CTCs/
DTCs. However, there is still no gold standard in the
definition of positive results in detection of CTCs/DTCs.
And validation studies are still lacking. An international
agreement of the definition of ‘positive’ CTCs in future
trial is necessary. Thirdly, logHR and SE results were ex-
tracted from either multivariate analysis or univariate
analysis studies. To ensure data integrity, we combined
these univariate analysis and multivariate analysis
together.Conclusion
In conclusion, available evidence supports that CTCs/
DTCs were significantly associated with advanced tumorstage, residual diseases, and treatment response, but not
with histological types and lymph node metastasis in
patients with ovarian cancer. Moreover, CTCs also were
significantly associated with a poorer survival. CTCs/
DTCs could be a reliable non-invasive prognostic marker
for ovarian cancer. Clinical management based on CTCs/
DTCs could be useful for determining which patients
would potentially benefit from adjuvant therapy.
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